← Every company
Natera Inc Patents
What Natera Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
NTRA on carbonthat →Filings on file
54
Granted
4
Still pending
50
Filed under
4 names
54 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHODS FOR ASSESSING GRAFT SUITABILITY FOR TRANSPLANTATIONC12Q 1/6851, C12Q 1/6881, C12Q 1/6848, C12Q 1/6883, C12Q2600/106Filed as Natera, Inc.2026-04-24Paula A. North | pending |
| TRANSFORMING LONGITUDINAL UNSTRUCTURED DIGITAL CLINICAL DOCUMENTS INTO STRUCTURED SCHEMAS AND INFERRING IMMUNOTHERAPY TREATMENT RESPONSE USING MACHINE LEARNINGFiled as NATERA, INC.2026-03-19THINH TRAN | pending |
| METHODS FOR LONGITUDINALLY ASSESSING DONOR-DERIVED CELL FREE DNA (DD-CFDNA) IN TRANSPLANT RECIPIENTSFiled as NATERA, INC.2026-02-09DAVID GIOVANNI BIAGINI | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2026-01-28Joshua Babiarz | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2026-01-28Joshua Babiarz | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2026-01-28Joshua BABIARZ | pending |
| METHODS FOR ENRICHING AND SEQUENCING NUCLEIC ACIDS FOR NON- INVASIVE CANCER TESTINGC12Q 1/6806, C12Q 1/6869, C12Q 1/6876, G16B 10/00, G16B 30/00, C12Q 1/6827, C12Q 1/6844, C12Q2600/156Filed as Natera, Inc.2026-01-23Allison Ryan | pending |
| TUMOR DETECTION AND CANCER MONITORINGFiled as NATERA, INC.2026-01-22ANASTASIA BUTSKOVA | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2026-01-14Joshua BABIARZ | pending |
| METHODS FOR ASSESSMENT AND TREATMENT OF RELAPSE OF ANTIBODY-MEDIATED ALLOGRAFT REJECTIONFiled as NATERA, INC.2025-12-12ZACHARY DEMKO | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6848, C12Q 1/686, C12Q 1/68, C12Q 1/6806, C12Q 1/6811, C12Q 1/6874, C12Q 1/6883, C12Q 1/6886, C12Q2600/156Filed as Natera, Inc.2025-12-05Joshua BABIARZ | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2025-12-01Joshua BABIARZ | pending |
| METHODS FOR TARGETED SEQUENCING OF CELL-FREE DNAG16B 20/10, C12Q 1/6883, G16B 40/00, G16B 20/00, G16B 25/00, G16B 40/20, G16B 30/00, C12Q 1/6827, C12Q 1/6855, C12Q 1/686, C12Q 1/6869, C12Q 1/6876, C12Q2600/118, C12Q2600/156, C12Q2600/158, C12Q2537/165Filed as Natera, Inc.2025-11-24Matthew RABINOWITZ | pending |
| METHODS FOR TARGETED SEQUENCING OF CELL-FREE DNAG16B 20/10, C12Q 1/6883, G16B 40/00, G16B 20/00, G16B 25/00, G16B 40/20, G16B 30/00, C12Q 1/6827, C12Q 1/6855, C12Q 1/686, C12Q 1/6869, C12Q 1/6876, C12Q2600/118, C12Q2600/156, C12Q2600/158, C12Q2537/165Filed as Natera, Inc.2025-11-24Matthew RABINOWITZ | pending |
| COMPOSITIONS AND METHODS FOR IDENTIFYING NUCLEIC ACID MOLECULESC12Q 1/6869, C12Q 1/6806, C12Q2525/179, C12Q2535/122, C12Q2563/179, C12Q2537/16Filed as Natera, Inc.2025-11-07Bernhard ZIMMERMANN | pending |
| METHOD FOR SEQUENTIAL PREPARATION OF NUCLEIC ACID LIBRARIESFiled as NATERA, INC.2025-10-15TUDOR POMPILIU CONSTANTIN | pending |
| METHODS AND COMPOSITIONS FOR SINGLE-GENE NON-INVASIVE PRENATAL TESTINGSFiled as NATERA, INC.2025-10-14RAVI VIJAYA SATYA | pending |
| METHODS FOR ASSESSMENT AND TREATMENT OF CHRONIC LUNG ALLOGRAFT DYSFUNCTIONFiled as NATERA, INC.2025-10-09DAVID ROSS | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6848, C12Q 1/686, C12Q 1/68, C12Q 1/6806, C12Q 1/6811, C12Q 1/6874, C12Q 1/6883, C12Q 1/6886, C12Q2600/156Filed as Natera, Inc.2025-09-12Joshua BABIARZ | pending |
| IMPROVED METHOD FOR METHYLATION BIOMARKER GENERATION AND ANALYSISFiled as NATERA, INC.2025-08-15TUDOR POMPILIU CONSTANTIN | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 5/20, G16B 20/00, G16B 20/40, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q 1/6827, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2025-08-14Joshua BABIARZ | pending |
| METHODS AND COMPOSITIONS FOR SINGLE-GENE NON-INVASIVE PRENATAL TESTINGSFiled as Natera, Inc.2025-08-01Ravi Vijaya Satya | pending |
| Method for identifying kidney allograft rejection genes in urine and utility of making those measurementsC12Q 1/6883, G16B 25/10, G16B 40/00, G16B 40/20, C12Q 1/6806, C12Q2600/158, C12Q2600/16, C12Q2600/178, G01N 33/6893, G01N2800/245, G01N2800/50, C12Q2600/112Filed as Natera, Inc.2025-08-01Alain MIR | pending |
| METHODS OF NUCLEIC ACID PREPARATION AND ANALYSISFiled as NATERA, INC.2025-07-17TRUPTI KAWLI | pending |
| METHODS FOR CANCER DETECTION AND MONITORINGC12Q 1/6886, C12Q 1/6827, C12Q2600/106, C12Q2600/112, C12Q2600/118, C12Q2600/156, C12Q2600/158Filed as Natera, Inc.2025-07-17Bernhard ZIMMERMANN | pending |
| METHODS AND COMPOSITIONS FOR AMPLIFYING METHYLATED NUCLEIC ACID MOLECULESFiled as NATERA, INC.2025-07-07JOEL PEL | pending |
| METHODS AND COMPOSITIONS FOR AMPLIFYING METHYLATED TARGET DNA MOLECULESC12Q 1/6827, C12Q 1/686, C12Q 1/48, C12Q 1/6806, C12Q 1/6813, C12Q 1/6851, C12Q 1/6855, C12Q 1/6869, C12Q 1/6886, C12Q2600/154, C12Y 207/07, C40B 70/00, C12Q2521/331, C12Q2525/191, C12Q2531/113, C12Q2537/159, C12Q2563/179Filed as Natera, Inc.2025-07-07Ting Wang | pending |
| METHODS FOR DETERMINATION AND TREATMENT OF RHESUS INCOMPATIBILTYFiled as NATERA, INC.2025-06-26TING WANG | pending |
| METHODS FOR PREDICTING AND SELECTING NEOANTIGENSG16H 50/50, G16B 15/30, G16H 20/10, G16B 20/30, G16B 20/20, G16B 40/20, G16B 30/00Filed as Natera, Inc2025-06-18Robert BURNS | pending |
| METHODS FOR PREDICTING AND SELECTING NEOANTIGENSFiled as NATERA, INC2025-06-18ROBERT BURNS | pending |
| NUCLEIC ACID ANALYSIS OF PERFUSION OR FLUSH FLUIDSC12Q 1/6881, C12Q 1/6883, C12Q2600/118Filed as Natera, Inc.2025-04-01Paul VAN HUMMELEN | pending |
| NON-INVASIVE METHODS OF ASSESSING TRANSPLANT REJECTION IN PREGNANT TRANSPLANT RECIPIENTSC12Q 1/6851, G16B 20/20, C12N 15/1093, C12Q 1/6806, C12Q 1/6874Filed as Natera, Inc.2025-04-01Jessica TANG | pending |
| METHODS FOR DETERMINATION AND MONITORING OF XENOTRANSPLANT REJECTION BY MEASURING NUCLEIC ACIDS OR PROTEINS DERIVED FROM THE XENOTRANSPLANTC12Q 1/6883, C12N2310/20, A61P 37/06, C12N 9/226, C12N 15/1096, C12N 15/111, C12Q 1/37, C12Q 1/6806, C12Q 1/6809, C12Q 1/6848, C12Q 1/6874, C12Q2600/106, C12Q2600/158, G01N 33/6893, G01N2333/922, G01N2800/245, G01N2800/52Filed as Natera, Inc.2025-04-01Tudor Pompiliu CONSTANTIN | pending |
| PREDICTED IMMUNOTHERAPY CLINICAL OUTPUTS FROM UNSTRUCTURED CLINICAL DOCUMENTS USING LARGE LANGUAGE MODELSFiled as Natera, Inc.2025-03-20Thinh Tran | pending |
| METHODS FOR LONGITUDINALLY ASSESSING DONOR-DERIVED CELL FREE DNA (DD-CFDNA) IN TRANSPLANT RECIPIENTSFiled as Natera, Inc.2025-02-19David Giovanni Biagini | pending |
| TUMOR DETECTION AND CANCER MONITORINGFiled as Natera, Inc.2025-01-22Anastasia Butskova | pending |
| METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGG16B 20/00, C12Q 1/6869, G16B 20/20, G16B 40/00, G16B 20/40, G16B 20/10, G16B 30/00, G06N 7/01, C12N 15/11, C12Q 1/6804, C12Q 1/6806, C12Q 1/6827, C12Q 1/6844, C12Q 1/6851, C12Q 1/6855, C12Q 1/686, C12Q 1/6862, C12Q 1/6874, C12Q 1/6876, C12Q 1/6881, C12Q 1/6883, C12Q2525/179, C12Q2527/113, C12Q2527/143, C12Q2537/143, C12Q2537/149, C12Q2537/159, C12Q2545/114, C12Q2600/156, C12Q2600/16, G01N 33/50, C12Q2537/161, C12Q2537/165, C12Q2531/101, C12Q2535/122, C12Q2549/119, C12Q2563/179Filed as Natera, Inc.2025-01-17Matthew RABINOWITZ | pending |
| METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCIC12Q 1/6883, G16B 20/20, G16B 40/00, G16B 20/00, G16B 20/10, C12Q 1/6806, C12Q 1/6809, C12Q 1/6811, C12Q 1/6844, C12Q 1/6848, C12Q 1/6851, C12Q 1/6855, C12Q 1/6858, C12Q 1/6869, C12Q 1/6874, C12Q2600/156, C12Q2527/107, C12Q2537/143, C12Q2531/113, C12Q2535/122, C12Q2563/159, C12Q2537/159, C12Q2545/114, C12Q2525/15, C12Q2525/155, C12Q2525/191, C12Q2563/179, C12Q2521/301, C12Q2521/319, C12Q2521/501, C12Q2531/125Filed as Natera, Inc.2025-01-17MATTHEW RABINOWITZ | 12509730 |
| METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGG16B 20/00, C12Q 1/6869, G16B 20/20, G16B 40/00, G16B 20/40, G16B 20/10, G16B 30/00, G06N 7/01, C12N 15/11, C12Q 1/6804, C12Q 1/6806, C12Q 1/6827, C12Q 1/6844, C12Q 1/6851, C12Q 1/6855, C12Q 1/686, C12Q 1/6862, C12Q 1/6874, C12Q 1/6876, C12Q 1/6881, C12Q 1/6883, C12Q2525/179, C12Q2527/113, C12Q2527/143, C12Q2537/143, C12Q2537/149, C12Q2537/159, C12Q2545/114, C12Q2600/156, C12Q2600/16, G01N 33/50, C12Q2537/161, C12Q2537/165, C12Q2531/101, C12Q2535/122, C12Q2549/119, C12Q2563/179Filed as Natera, Inc.2025-01-17MATTHEW RABINOWITZ | 12494267 |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2025-01-17Joshua BABIARZ | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2025-01-17Joshua BABIARZ | pending |
| METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCIC12Q 1/6855, C12Q 1/6883, G16B 20/20, G16B 40/00, G16B 20/00, G16B 20/10, C12Q 1/6809, C12Q 1/6811, C12Q 1/6844, C12Q 1/6848, C12Q 1/6851, C12Q 1/6869, C12Q 1/6874, C12Q2600/156, C12Q2531/113, C12Q2535/122, C12Q2537/143, C12Q2549/119, C12Q2563/179Filed as Natera, Inc.2025-01-17MATTHEW RABINOWITZ | 12545960 |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2025-01-17Joshua Babiarz | pending |
| METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCIC12Q 1/6883, G16B 20/20, G16B 40/00, G16B 20/00, G16B 20/10, C12Q 1/6806, C12Q 1/6809, C12Q 1/6811, C12Q 1/6844, C12Q 1/6848, C12Q 1/6851, C12Q 1/6855, C12Q 1/6858, C12Q 1/6869, C12Q 1/6874, C12Q2600/156, C12Q2527/107, C12Q2537/143, C12Q2531/113, C12Q2535/122, C12Q2563/159, C12Q2537/159, C12Q2545/114, C12Q2525/15, C12Q2525/155, C12Q2525/191, C12Q2563/179, C12Q2521/301, C12Q2521/319, C12Q2521/501, C12Q2531/125Filed as Natera, Inc.2025-01-17Matthew RABINOWITZ | 12692544 |
| METHYLATION BIOMARKER GENERATION AND ANALYSISFiled as NATERA, INC.2025-01-07OMID SHAMS SOLARI | pending |
| COMPOSITIONS AND METHODS FOR IDENTIFICATION OF CHROMOSOMAL MICRODELETIONSC12Q 1/6827, C12Q 1/686, C12Q 1/48, C12Q 1/6806, C12Q 1/6809, C12Q 1/6851, C12Q 1/6869, C12Q 1/6886, C12Q2600/156, C12Q2600/166, C12Y 207/07, C12Q2545/101, C12Q2563/185Filed as Natera, Inc.2024-12-20Hemant Pawar | pending |
| METHODS FOR ASSESSMENT AND TREATMENT OF RELAPSE OF ANTIBODY-MEDIATED ALLOGRAFT REJECTIONFiled as Natera, Inc.2024-12-18Zachary DEMKO | pending |
| METHODS FOR DETERMINATION AND MONITORING OF TRANSPLANT REJECTION BY MEASURING RNAC12Q 1/6883, C12Q 1/485, C12Q 1/6806, C12Q2600/178, C12Q2521/301, C12Q2521/107, C12Q2537/143, C12Q2535/122Filed as Natera, Inc.2024-11-18Alain Mir | pending |
| METHODS FOR DETECTING RHD INCOMPATIBILTY IN PREGNANT BLOOD AND PLASMA SAMPLESFiled as NATERA, INC.2024-11-01XIAOKE WANG | pending |
| METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCIC12Q 1/6883, C12Q 1/6809, C12Q 1/6811, C12Q 1/6844, C12Q 1/6848, C12Q 1/6851, C12Q 1/6855, C12Q 1/6869, C12Q 1/6874, C12Q2600/156Filed as Natera, Inc.2024-10-30Joshua BABIARZ | pending |
| METHOD FOR SEQUENTIAL PREPARATION OF NUCLEIC ACID LIBRARIESFiled as Natera, Inc.2024-10-16Tudor Pompiliu CONSTANTIN | pending |
| METHODS AND COMPOSITIONS FOR SINGLE-GENE NON-INVASIVE PRENATAL TESTINGSFiled as Natera, Inc.2024-10-14Ravi Vijaya Satya | pending |
| METHODS FOR ASSESSMENT AND TREATMENT OF CHRONIC LUNG ALLOGRAFT DYSFUNCTIONFiled as Natera, Inc.2024-10-11David Ross | pending |
| DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSC12Q 1/6806, C12Q 1/6869, C12Q 1/6886, G16H 10/40, G16H 50/20, G06N 20/00, G16B 15/00, G16B 20/20, G16Z 99/00, G16B 40/00, G16B 25/20, G16B 20/00, G16B 20/10, G16B 25/00, G16B 40/20, G06N 7/01, C12Q2539/10, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2600/172Filed as Natera, Inc.2024-10-03Joshua BABIARZ | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on NTRA
Company overviewEverything on NTRA in one place, with the price.SEC filingsWhat NTRA's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat NTRA's own officers and directors buy and sell.Planned salesSales NTRA insiders have filed notice of.Executive payWhat NTRA awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in NTRA.Funds holding itWhich funds and ETFs hold NTRA, and how big a bet.LobbyingWhat NTRA spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on NTRA's account, and who they worked for.Federal contractsWhat federal agencies pay NTRA.